Evaluating the effects of Salmeterol/Fluticasone in stable COPD patients by inflammatory factors in exhaled breath condensate

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-12002052

Enrollment

Unknown

Registered

2012-03-29

Start date

2011-02-04

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructinv pulmonary disease

Interventions

one:Salmeterol/Fluticasone

Eligibility

Sex/Gender

All

Age

50 Years to 75 Years

Inclusion criteria

Inclusion criteria: aged 40-75 yrs; ex-smoke for more than 1 year or non-smokers; symptoms compatible with COPD (cough, sputum production, chest tightness or short of breath after activity); refrained from using corticosteroids or antibiotic at least 8 weeks or long-acting beta 2 agonists at least 2 weeks before enrolled to the study; subjects had been free from respiratory tract infection or COPD exacerbation for 12 weeks prior to the spirometry; post-bronchodilator FEV1<80%, FEV1/FVC ratio<0.7; no combined other active lung diseases, diabetes or diseases needed long-term corticosteroids therapy.

Exclusion criteria

Exclusion criteria: Exclusion criteria were: patients had exacerbation during observation or they couldn't insist SFC treatment for 12 weeks. With other diseases like hypertention, diabetes, chronic respiratory disease and rheumatism.

Design outcomes

Primary

Measure	Time frame
exhaled breath condensate;	—

Countries

China

Contacts

Public ContactPing Huang

sznshp@263.net+86 13603078376

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026